PCRX Stock Summary and Trading Ideas (Pacira Biosciences | NASDAQ:PCRX)

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

What symbol and exchange does Pacira Biosciences shares trade?

Pacira Biosciences trades on the NASDAQ stock market under the symbol PCRX.

What is Pacira Biosciences stock price doing today?

As of April 2, 2026, PCRX stock price declined to $22.70 with 548,838 million shares trading.

What is Pacira Biosciences's Beta?

PCRX has a beta of 0.74, meaning it tends to be less sensitive to market movements. PCRX has a correlation of 0.10 to the broad based SPY ETF.

How much is Pacira Biosciences worth?

PCRX has a market cap of $932.97 million. This is considered a Small Cap stock.

How much money does Pacira Biosciences make?

Last quarter Pacira Biosciences reported $197 million in Revenue and $.57 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.21.

What is the highest and lowest price Pacira Biosciences traded in the last 3 year period?

In the last 3 years, PCRX traded as high as $48.60 and as low as $11.16.

What are the top ETFs holding Pacira Biosciences?

The top ETF exchange traded funds that PCRX belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.

Is Pacira Biosciences (PCRX) a good investment?

PCRX has underperformed the market in the last year with a return of -5.7%, while the SPY ETF gained +18.2%. In the last 3 month period, PCRX fell short of the market, returning -12.3%, while SPY returned -3.6%. However, in the most recent 2 weeks PCRX has outperformed the stock market by returning +3.1%, while SPY returned -0.6%.

What are the support and resistance levels for Pacira Biosciences (PCRX)?

PCRX support price is $22.21 and resistance is $23.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCRX shares will trade within this expected range on the day.